22-644 Phase I
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma
Search Cancer Clinical Trials
Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
13 results
21-245 Phase II
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma or Multiple Myeloma
23-369 Phase I
A Phase 1b, Open-Label Study of Elranatamab in combination with Carzfilzomib plus Dexamethasone and Elranatmab in combination with PF-0790180 in Participants with relapsed refractory Multiple Myeloma
22-448 Phase II
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
22-166 Phase II
A Phase 1B/2, Open Label Umbrella Study of Elranatamab (PF-06863135), A B-CELL Maturation Antigen (BCMA) CD3 Bispecific Antibody, In Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma
23-402 Phase II
A phase 2 study of elranatamab as consolidation after idecabtagene vicleucel in relapsed refractory multiple myeloma
18-604 Phase II
A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2).
22-631 Phase III
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy
20-518 Phase I
A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
22-533 Phase II
A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Showing 1 - 10 of 13 results